Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Biotech
Anti-aging biotech NewLimit nabs $435M to rejuvenate old cells
Backed by Peter Thiel's Founders Fund, NewLimit looks to push a liver-targeting mRNA therapeutic into the clinic next year.
Darren Incorvaia
Jun 2, 2026 1:00pm
FDA qualifies 1st AI drug development tool in MASH
Dec 9, 2025 12:12pm
AstraZeneca drops MASH drug over disappointing data
Nov 6, 2025 5:21am
Fierce Pharma
Big Pharma bets big on MASH with a new combo playbook
Oct 17, 2025 9:30am
FDA considers new liver trial endpoint, sending MASH shares up
Aug 28, 2025 11:25am
Roche launches liver fibrosis blood test for MASLD
May 7, 2025 10:30am
